Related Experiment Video
Updated: Jul 31, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Role of Psychedelics in Treatment-Resistant Depression
Shubham Kamal1, Manish Kumar Jha2, Rajiv Radhakrishnan3
1Department of Psychiatry, School of Medicine, Yale University, 300 George Street, Suite 901, New Haven, CT 06511, USA.
Abstract:
There is increasing interest in exploring the therapeutic potential of psychedelics in treatment-resistant depression (TRD). Classic psychedelics (such as psilocybin, LSD, ayahuasca/DMT), and atypical psychedelics (such as ketamine) have been studied in TRD. The evidence for the classic psychedelics TRD is limited at the present time; early studies however show promising results. There is also recognition that psychedelic research may be subject to a "hype bubble" at the present time. Future studies focused on delineating necessary ingredients of psychedelic treatments and the neurobiological basis of their effects, will help pave the way for the clinical use of these compounds.
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Antidepressant Drugs: MAOIs and Other Agents
CNS Stimulants: Psychedelic Agents
Electroconvulsive Therapy
Drug Therapy
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview

